基于分子医学的IBD治疗策略 - 我们将其视为个人!
Viktoria Hentschel1, Jochen Klaus1
1Department of Internal Medicine I, University Clinic Ulm, Ulm, Germany.
Frontiers in gastroenterology (Lausanne, Switzerland)
|March 13, 2026
概括
识别患者的生物签名对于定制炎性肠病 (IBD) 治疗至关重要. 这种方法有助于避免过度治疗惰的病例,并确保有效的免疫抑制攻击性疾病过程 (克罗恩氏病).
科学领域:
- 胃肠道学和免疫学
- 分子诊断学 分子诊断学
- 个性化医疗是个性化的医疗.
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),可以呈现出侵略性或惰性的疾病过程.
- 有效的免疫抑制对于侵略性IBD至关重要,以防止组织损伤,但必须避免过度治疗惰的病例.
- 目前的治疗策略面临着二分法:不充分治疗侵袭性疾病或过度治疗惰性疾病.
研究的目的:
- 解决基于生物特征的可靠患者分类的需求,以预测IBD的预后和治疗反应.
- 介绍和讨论疾病前管理 (PreM) 和更严格的疾病前管理 (PerM) 的概念,以提供个性化的IBD护理.
- 审查关键研究结果,重点关注分子诊断,以实现个性化的IBD管理.
主要方法:
- 关于个人化IBD护理的已发表研究的综述.
- 专注于分子诊断及其临床适用性.
- 基于生物特征的分类分析,用于预后和治疗反应.
主要成果:
- 关键研究结果强调了分子诊断在IBD护理中的潜力.
- 基于生物特征的分类为精确的治疗策略提供了一条道路.
- 像PreM和PerM这样的概念正在出现,用于个性化患者管理.
结论:
- 个性化IBD护理需要使用生物签名可靠的患者分层.
- 分子诊断是评估预后和指导治疗选择的关键.
- 像PreM和PerM这样的个性化方法旨在优化治疗结果,避免IBD的不良事件.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
998
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
998
Drugs for Treatment of Ulcerative Colitis in IBD
589
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
589
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
693
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
693


